Product
AXL1717
1 clinical trial
6 indications
Indication
GlioblastomaIndication
GliosarcomaIndication
Anaplastic AstrocytomaIndication
OligodendrogliomaIndication
Anaplastic OligoastrocytomaIndication
anaplastic ependymomaClinical trial
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant AstrocytomasStatus: Terminated, Estimated PCD: 2015-12-01